- Quince Therapeutics announced **completed enrollment** of **105 patients** in its pivotal **Phase 3 NEAT trial** for Ataxia Telangiectasia (AT), with **top-line results expected in Q1 2026**.  **[1662774_2164907_0]** **[1662774_2164907_4]** **[1662774_2164907_10]** 
- The NEAT trial is under a **Special Protocol Assessment (SPA)** with the FDA, positioning a positive outcome as a potential single pivotal trial for approval of EDSP, which has **Orphan Drug** and **Fast Track Designations**.  **[1662774_2164907_8]** **[1662774_2164907_17]** 
- The company estimates a U.S. market of approximately **5,000 AT patients**, projecting a **$1 billion+ commercial opportunity** for EDSP as a potential first-to-market therapy.  **[1662774_2164907_18]** **[1662774_2164907_23]** 
- Quince Therapeutics reported a cash balance of approximately **$35 million** at the end of Q2, extending its financial runway through Phase 3 data and into **2026**.  **[1662774_2164907_23]**

Quince Therapeutics (QNCX)